• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen.

作者信息

Thompson Meghan C, Harrup Rosemary A, Coombs Catherine C, Roeker Lindsey E, Pu Jeffrey J, Choi Michael Y, Barr Paul M, Allan John N, Šimkovič Martin, Leslie Lori, Rhodes Joanna, Chong Elise A, Kamdar Manali, Skarbnik Alan, Lansigan Frederick, McCall Brittany, Saja Khalid, Dyer Martin J S, Walter Harriet S, Lefebure Marcus, Thadani-Mulero Maria, Boyer Michelle, Biondo Juliana, Sail Kavita, Manzoor Beenish S, Furman Richard, Bantilan Kurt S, Goy Andre, Feldman Tatyana, Labella Dominic, Schuster Stephen J, Park Jae, Palomba Lia, Zelenetz Andrew, Eyre Toby A, Kater Arnon P, Seymour John F, Mato Anthony R

机构信息

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY.

Royal Hobart Hospital, Tasmania, Australia.

出版信息

Blood Adv. 2022 Aug 9;6(15):4553-4557. doi: 10.1182/bloodadvances.2022007812.

DOI:10.1182/bloodadvances.2022007812
PMID:
35736670
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9636322/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56d0/9636322/90a4a2182d91/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56d0/9636322/90a4a2182d91/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56d0/9636322/90a4a2182d91/gr1.jpg

相似文献

1
Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen.在先前基于维奈克拉的治疗方案后，对慢性淋巴细胞白血病患者进行维奈克拉再治疗。
Blood Adv. 2022 Aug 9;6(15):4553-4557. doi: 10.1182/bloodadvances.2022007812.
2
Venetoclax, the first BCL-2 inhibitor for use in patients with chronic lymphocytic leukemia.维奈克拉，首款用于慢性淋巴细胞白血病患者的BCL-2抑制剂。
Clin Adv Hematol Oncol. 2019 Aug;17(8):440-443.
3
Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy.接受维奈托克单药治疗的慢性淋巴细胞白血病患者凋亡机制中复发性基因组改变的鉴定
Am J Hematol. 2022 Feb 1;97(2):E47-E51. doi: 10.1002/ajh.26411. Epub 2021 Nov 24.
4
Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor.维奈托克用于接受一种以上B细胞受体途径抑制剂治疗后病情进展的慢性淋巴细胞白血病患者。
Br J Haematol. 2019 Jun;185(5):961-966. doi: 10.1111/bjh.15666. Epub 2018 Nov 27.
5
Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study.在初治的TP53基因异常的慢性淋巴细胞白血病患者中持续使用维奈托克：一项慢性淋巴细胞白血病领域研究
Am J Hematol. 2023 Sep;98(9):E237-E240. doi: 10.1002/ajh.27009. Epub 2023 Jun 29.
6
An update of venetoclax and obinutuzumab in chronic lymphocytic leukemia.维奈托克和奥滨尤妥珠单抗在慢性淋巴细胞白血病中的更新。
Future Oncol. 2021 Feb;17(4):371-387. doi: 10.2217/fon-2020-0640. Epub 2020 Oct 16.
7
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.美国接受维奈托克治疗的慢性淋巴细胞白血病患者的真实世界结局和管理策略。
Haematologica. 2018 Sep;103(9):1511-1517. doi: 10.3324/haematol.2018.193615. Epub 2018 Jun 7.
8
Venetoclax (Venclexta) for chronic lymphocytic leukemia.维奈克拉（维可来）用于治疗慢性淋巴细胞白血病。
Med Lett Drugs Ther. 2016 Aug 1;58(1500):101-2.
9
Treatment with Venetoclax for Chronic Lymphocytic Leukemia with the Highest Known White Blood Cell Count: Safe and Effective.使用维奈托克治疗已知白细胞计数最高的慢性淋巴细胞白血病：安全有效。
Turk J Haematol. 2021 Dec 7;38(4):344-346. doi: 10.4274/tjh.galenos.2021.2021.0435. Epub 2021 Nov 18.
10
Venetoclax Yields Strong Responses in CLL.维奈托克在 CLL 中产生强烈应答。
Cancer Discov. 2016 Feb;6(2):113-4. doi: 10.1158/2159-8290.CD-NB2015-180. Epub 2015 Dec 23.

引用本文的文献

1
Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy.BTK抑制剂治疗后慢性淋巴细胞白血病的耐药机制及应对方法
Leuk Lymphoma. 2025 Jul;66(7):1176-1188. doi: 10.1080/10428194.2025.2466101. Epub 2025 Feb 19.
2
Improving Treatment Options for Patients with Double Refractory CLL.改善双重难治性慢性淋巴细胞白血病患者的治疗选择
Cancers (Basel). 2025 Jan 27;17(3):430. doi: 10.3390/cancers17030430.
3
Risk-stratification in frontline CLL therapy: standard of care.一线慢性淋巴细胞白血病治疗中的风险分层：治疗标准

本文引用的文献

1
Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" (Shakespeare).在针对 CLL/SLL 的靶向治疗时代识别未满足的需求：“过去的一切都是序幕”（莎士比亚）。
Clin Cancer Res. 2022 Feb 15;28(4):603-608. doi: 10.1158/1078-0432.CCR-21-1237.
2
Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition.对同时对 BCL2 和 BTK 抑制具有耐药性的 CLL 患者的治疗结局。
Blood Adv. 2021 Oct 26;5(20):4054-4058. doi: 10.1182/bloodadvances.2021005083.
3
Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy.
Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):457-466. doi: 10.1182/hematology.2024000656.
4
Consensus recommendations from the 2024 Lymphoma Research Foundation workshop on treatment selection and sequencing in CLL or SLL.2024年淋巴瘤研究基金会关于慢性淋巴细胞白血病或小淋巴细胞淋巴瘤治疗选择与序贯治疗的共识建议。
Blood Adv. 2025 Mar 11;9(5):1213-1229. doi: 10.1182/bloodadvances.2024014474.
5
Treatment Sequencing in Chronic Lymphocytic Leukemia in 2024: Where We Are and Where We Are Headed.2024年慢性淋巴细胞白血病的治疗顺序：我们所处的位置以及前进的方向。
Cancers (Basel). 2024 May 25;16(11):2011. doi: 10.3390/cancers16112011.
6
Current Therapeutic Sequencing in Chronic Lymphocytic Leukemia.慢性淋巴细胞白血病的当前治疗顺序
Hematol Rep. 2024 Apr 30;16(2):270-282. doi: 10.3390/hematolrep16020027.
7
Taking the Next Step in Double Refractory Disease: Current and Future Treatment Strategies for Chronic Lymphocytic Leukemia.双难治性疾病的下一步进展：慢性淋巴细胞白血病的当前及未来治疗策略
Onco Targets Ther. 2024 Mar 8;17:181-198. doi: 10.2147/OTT.S443924. eCollection 2024.
8
Update on the management of relapsed/refractory chronic lymphocytic leukemia.复发/难治性慢性淋巴细胞白血病的治疗进展。
Blood Cancer J. 2024 Feb 21;14(1):33. doi: 10.1038/s41408-024-01001-1.
9
Frontline Therapy of CLL-Changing Treatment Paradigms.CLL 的一线治疗——改变治疗模式。
Curr Hematol Malig Rep. 2024 Apr;19(2):65-74. doi: 10.1007/s11899-024-00726-x. Epub 2024 Feb 10.
10
Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon.维奈克拉联合利妥昔单抗对曾接受布鲁顿酪氨酸激酶抑制剂（BTKi）治疗的慢性淋巴细胞白血病（CLL）患者有活性，但持久的无治疗缓解并不常见。
Blood Adv. 2024 Mar 26;8(6):1439-1443. doi: 10.1182/bloodadvances.2023011327.
维奈托克联合利妥昔单抗治疗复发 CLL：连续或有限疗程治疗的 5 年随访。
Blood. 2021 Sep 9;138(10):836-846. doi: 10.1182/blood.2020009578.
4
How I treat chronic lymphocytic leukemia after venetoclax.维奈托克治疗慢性淋巴细胞白血病后的体会
Blood. 2021 Aug 5;138(5):361-369. doi: 10.1182/blood.2020008502.
5
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.维奈托克联合奥滨尤妥珠单抗与苯丁酸氮芥联合奥滨尤妥珠单抗治疗初治慢性淋巴细胞白血病（CLL14）：一项多中心、开放标签、随机、3 期临床试验的随访结果。
Lancet Oncol. 2020 Sep;21(9):1188-1200. doi: 10.1016/S1470-2045(20)30443-5.
6
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy.评估 Venetoclax 停药后治疗 CLL 的疗效表明 BTK 抑制是一种有效的策略。
Clin Cancer Res. 2020 Jul 15;26(14):3589-3596. doi: 10.1158/1078-0432.CCR-19-3815. Epub 2020 Mar 20.
7
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.维奈托克联合奥滨尤妥珠单抗治疗伴有合并症的 CLL 患者
N Engl J Med. 2019 Jun 6;380(23):2225-2236. doi: 10.1056/NEJMoa1815281. Epub 2019 Jun 4.
8
Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.维奈托克联合利妥昔单抗治疗复发/难治性慢性淋巴细胞白血病的持续时间：MURANO Ⅲ期研究的治疗后随访结果，可消除微小残留病灶并延长生存。
J Clin Oncol. 2019 Feb 1;37(4):269-277. doi: 10.1200/JCO.18.01580. Epub 2018 Dec 3.
9
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.维奈托克联合利妥昔单抗治疗复发或难治性慢性淋巴细胞白血病。
N Engl J Med. 2018 Mar 22;378(12):1107-1120. doi: 10.1056/NEJMoa1713976.
10
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.iwCLL 指南：用于 CLL 的诊断、治疗指征、疗效评估和支持性管理。
Blood. 2018 Jun 21;131(25):2745-2760. doi: 10.1182/blood-2017-09-806398. Epub 2018 Mar 14.